Ranked by reported Q1 2026 13F market value
Share of total reported institutional value in EPRX held by the largest 10 / 25 filers.
| # | Institution | Shares Held | Market Value | QoQ Change | Ownership % | % of Fund |
|---|---|---|---|---|---|---|
| 1 | Affinity Asset Advisors, LLC | 1.6M | $11.5M | +429.7% | 4.746% | 0.67% |
| 2 | Vivo Capital, LLC | 1.4M | $9.8M | 0.0% | 4.032% | 0.82% |
| 3 | BALYASNY ASSET MANAGEMENT LLC | 1.4M | $9.8M | 0.0% | 4.032% | 0.03% |
| 4 | Ikarian Capital, LLC | 1.2M | $8.8M | +99.1% | 3.628% | 0.94% |
| 5 | GREAT POINT PARTNERS LLC | 1.2M | $8.7M | 0.0% | 3.584% | 2.13% |
| 6 | SCOTIA CAPITAL INC. | 1.3M | $7.2M | +4.3% | 4.009% | 0.03% |
| 7 | Point72 Asset Management, L.P. | 968K | $7.0M | +35.9% | 2.890% | 0.01% |
| 8 | UBS Group AG | 763K | $5.5M | +246.6% | 2.278% | 0.00% |
| 9 | Redmile Group, LLC | 700K | $5.1M | — | 2.091% | 0.34% |
| 10 | Rubric Capital Management LP | 691K | $5.0M | — | 2.064% | 0.06% |
| 11 | Squadron Capital Management LLC | 680K | $4.9M | +36.0% | 2.031% | 2.04% |
| 12 | Ally Bridge Group (NY) LLC | 660K | $4.8M | +66.0% | 1.972% | 4.45% |
| 13 | PFM Health Sciences, LP | 541K | $3.9M | — | 1.615% | 0.39% |
| 14 | AMERIPRISE FINANCIAL INC | 524K | $3.8M | — | 1.566% | 0.00% |
| 15 | Woodline Partners LP | 441K | $3.2M | — | 1.316% | 0.01% |
| 16 | Seven Fleet Capital Management LP | 434K | $3.1M | — | 1.295% | 1.00% |
| 17 | Alyeska Investment Group, L.P. | 375K | $2.7M | — | 1.120% | 0.01% |
| 18 | Velan Capital Investment Management LP | 352K | $2.5M | 0.0% | 1.051% | 1.60% |
| 19 | SummitTX Capital, L.P. | 328K | $2.4M | +86.4% | 0.980% | 0.07% |
| 20 | Aisling Capital Management LP | 325K | $2.4M | — | 0.971% | 0.49% |
| 21 | BOOTHBAY FUND MANAGEMENT, LLC | 324K | $2.3M | +107.1% | 0.967% | 0.06% |
| 22 | DV Trading LLC | 276K | $2.0M | — | 0.824% | 0.05% |
| 23 | BANK OF AMERICA CORP /DE/ | 268K | $1.9M | +5.9% | 0.801% | 0.00% |
| 24 | ROYAL BANK OF CANADA | 261K | $1.9M | +33.2% | 0.781% | 0.00% |
| 25 | CITADEL ADVISORS LLC | 230K | $1.7M | — | 0.688% | 0.00% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). “% of Fund” shows how much of that investor’s total 13F portfolio is invested in EPRX — a direct measure of their conviction.
Filings activity in EPRX during Q1 2026, grouped by how each filer changed its position.
8 quarters of 13F filings · Δ columns show change vs prior quarter
| Quarter | Inst. Holders | Δ Holders | Ownership % | Δ Ownership | Total 13F Value | Δ Value |
|---|---|---|---|---|---|---|
| Q1 2026 | 53 | +51% | 63.75% | +26.88 pp | $129M | +73% |
| Q4 2025 | 35 | +30% | 36.87% | +11.69 pp | $75M | +46% |
| Q3 2025 | 27 | +80% | 25.18% | +19.90 pp | $51M | +377% |
| Q2 2025 | 15 | +25% | 5.28% | +1.78 pp | $11M | +51% |
| Q1 2025 | 12 | +20% | 3.50% | +0.71 pp | $7M | +26% |
| Q4 2024 | 10 | +11% | 2.79% | +0.54 pp | $6M | +24% |
| Q3 2024 | 9 | +0.0% | 2.25% | +0.06 pp | $5M | +2.5% |
| Q2 2024 | 9 | — | 2.19% | — | $4M | — |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Δ columns compare to the immediately prior filed quarter.
Quick answers to the most common questions about buying EPRX stock.
Based on Q1 2026 13F filings, institutional ownership of Eupraxia Pharmaceuticals Inc. stands at 63.7%, held across 53 reporting institutions.
Affinity Asset Advisors, LLC is the largest reported institutional holder of EPRX, with approximately 1,589,005 shares worth $0.01B as of Q1 2026.
Yes — 2 widely-followed marquee investors appear among the top 25 institutional holders of EPRX, including Point72 Asset Management, L.P., CITADEL ADVISORS LLC.
Our composite Smart Money Score for EPRX is 76 out of 100 (Bullish). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.
21 institutions opened new positions in EPRX during Q1 2026, while 3 fully exited. 17 added to existing positions and 15 trimmed.
EPRX institutional ownership rose by 26.88 percentage points quarter-over-quarter, with a net change of +18 holders.
The top 10 institutions account for 60.8% of all reported 13F value in EPRX, and the top 25 account for 94.6%.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.
Eupraxia Pharmaceuticals Inc. (EPRX) Institutional Ownership